CarnaBio USA

Carna Biosciences is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative small molecule kinase inhibitors to treat serious unmet medical needs in oncology and autoimmune diseases. Leveraging its proprietary kinase discovery platform and extensive library of kinase proteins, the company provides high-quality drug discovery services alongside its internal pipeline development. Its lead programs include highly selective, non-covalent BTK inhibitors designed to overcome resistance in B-cell malignancies and provide new options for inflammatory disorders. CarnaBio USA serves as the company's primary hub for business development and clinical operations in North America.